DENTSPLY SIRONA (NASDAQ:XRAY) Trading Down 8.4% – What’s Next?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY)’s share price fell 8.4% during mid-day trading on Friday . The stock traded as low as $12.08 and last traded at $12.0640. Approximately 1,294,629 shares traded hands during trading, a decline of 74% from the average daily volume of 5,021,003 shares. The stock had previously closed at $13.17.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results
• Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on XRAY shares. UBS Group cut their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Piper Sandler upped their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Mizuho lowered their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. BMO Capital Markets reiterated a “market perform” rating and issued a $13.00 target price on shares of DENTSPLY SIRONA in a report on Friday. Finally, Citigroup initiated coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $13.54.

DENTSPLY SIRONA Stock Performance

The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The company has a market cap of $2.43 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 1.44 and a beta of 0.85. The stock has a 50-day moving average price of $11.77 and a 200 day moving average price of $11.89.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. The business had revenue of $898.00 million for the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The firm’s revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts anticipate that DENTSPLY SIRONA Inc. will post 1.45 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian T. Gladden bought 9,985 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the purchase, the director owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Brian P. Mckeon purchased 10,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 35,160 shares of company stock worth $351,179 over the last ninety days. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA in the 4th quarter valued at $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. Farther Finance Advisors LLC boosted its position in DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 2,051 shares during the period. Finally, Performa Ltd US LLC boosted its position in DENTSPLY SIRONA by 116.1% during the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 2,283 shares during the period. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.